2015
DOI: 10.1093/brain/awv287
|View full text |Cite
|
Sign up to set email alerts
|

c-Myc–miR-29c–REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma

Abstract: Resistance to temozolomide poses a major clinical challenge in glioblastoma multiforme treatment, and the mechanisms underlying the development of temozolomide resistance remain poorly understood. Enhanced DNA repair and mutagenesis can allow tumour cells to survive, contributing to resistance and tumour recurrence. Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolomide-resistant cells, and resistant-xenograft models, we report that loss of miR-29c via c-Myc drives the acquisition o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
48
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
1
1

Relationship

3
6

Authors

Journals

citations
Cited by 58 publications
(49 citation statements)
references
References 73 publications
0
48
0
1
Order By: Relevance
“…Overexpressed Myc is a strong oncogene and has been explored in multiple types of cancer including glioma and GBM. It has been shown that c-Myc negatively regulates the tumor suppressor gene PTEN (Guo et al 2013) and is involved in resistance to temozolomide therapy (Luo et al 2015). Besides these effects it is strongly involved in metabolic reprogramming in glioma.…”
Section: Metabolic Compensations To Anti-tumor Therapymentioning
confidence: 99%
“…Overexpressed Myc is a strong oncogene and has been explored in multiple types of cancer including glioma and GBM. It has been shown that c-Myc negatively regulates the tumor suppressor gene PTEN (Guo et al 2013) and is involved in resistance to temozolomide therapy (Luo et al 2015). Besides these effects it is strongly involved in metabolic reprogramming in glioma.…”
Section: Metabolic Compensations To Anti-tumor Therapymentioning
confidence: 99%
“…FISH analysis was performed on human tissues and GBM cells as previously described [14]. IHC was performed on mice xenogeneic tumor tissues as previously described [14].…”
Section: Fluorescence In Situ Hybridization (Fish) and Immunohistochementioning
confidence: 99%
“…Murine xenograft models of human GBM were performed as described previously (20). See Supplementary Material for details.…”
Section: Subcutaneous and Orthotopic Xenograft Studiesmentioning
confidence: 99%